Half of the AML samples were sensitive to idasanutlin, with less than 80% cell viability at 24 h treatment with 1 μM compound, comprising six FLT3wt and eight FLT3-ITD AML samples. This evidence concerns the gene FLT3 and acute myeloid leukemia.